#1 Clinical Trials Search in Europe

Dactinomycin

Dactinomycin, also known as Actinomycin D, is an important chemotherapy drug being studied in various clinical trials for the treatment of different types of cancer. This article explores recent research on dactinomycin’s use in combination therapies and its potential benefits for patients with conditions like gestational trophoblastic neoplasia, rhabdomyosarcoma, and other rare cancers.

Table of Contents

What is Dactinomycin?

Dactinomycin, also known as Actinomycin D or Cosmegen, is an antineoplastic agent (a drug used to treat cancer) that belongs to a class of medications called polypeptide antibiotics[1]. This medication has been used in cancer treatment since the 1960s, particularly in pediatric oncology (childhood cancers)[2].

Conditions Treated with Dactinomycin

Dactinomycin is used to treat various types of cancers, including:

  • Rhabdomyosarcoma: A type of soft tissue cancer that develops in muscles[3]
  • Wilms tumor: A type of kidney cancer that primarily affects children[2]
  • Ewing’s sarcoma: A rare type of cancer that occurs in bones or in the soft tissue around the bones[4]
  • Gestational trophoblastic neoplasia (GTN): A group of rare tumors that form in the uterus during pregnancy[5]
  • Pleuropulmonary blastoma (PPB): A rare childhood cancer that occurs in the lungs or in the tissue that covers the lungs[1]
  • Testicular cancer: Cancer that develops in the testicles[6]

How Dactinomycin Works

Dactinomycin works by interfering with the DNA in cancer cells. It binds to the DNA, preventing the cells from making copies of themselves and from producing proteins they need to survive. This action helps to stop the growth and spread of cancer cells in the body[7].

How Dactinomycin is Administered

Dactinomycin is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of administration can vary depending on the specific condition being treated, the patient’s age, weight, and overall health status. Some common dosing regimens include:

  • For children 3 years and older: 0.045 mg/kg (with a maximum dose of 2.5 mg) given intravenously once[1]
  • For adults: 1.25 mg/m² (with a maximum dose of 2 mg) given intravenously every 2 weeks[5]

It’s important to note that Dactinomycin should not be given at the same time as radiation therapy[8].

Dactinomycin in Combination Therapies

Dactinomycin is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combination therapies include:

  • VAC: Vincristine, Actinomycin D (Dactinomycin), and Cyclophosphamide[1]
  • IVADo: Ifosfamide, Vincristine, Actinomycin D (Dactinomycin), and Doxorubicin[1]
  • GAMEC: PEG-filgrastim, Actinomycin D (Dactinomycin), Methotrexate, Etoposide, and Cisplatin[6]

Potential Side Effects

Like all chemotherapy drugs, Dactinomycin can cause side effects. These may include:

  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Increased risk of infections due to lowered white blood cell counts
  • Mouth sores
  • Skin rashes or changes in skin pigmentation

Your healthcare team will monitor you closely for these and other potential side effects during treatment[8].

Ongoing Research and Clinical Trials

Researchers continue to study Dactinomycin to better understand its effects and to find new ways to use it in cancer treatment. Some ongoing areas of research include:

  • Investigating the optimal dosing of Dactinomycin, especially in young children[2]
  • Studying the effectiveness of Dactinomycin in combination with newer targeted therapies[7]
  • Exploring the use of Dactinomycin in adaptive therapy approaches for rhabdomyosarcoma[8]
  • Evaluating Dactinomycin as part of first-line treatment for gestational trophoblastic neoplasia[5]

If you’re interested in participating in a clinical trial involving Dactinomycin, talk to your doctor about potential opportunities and whether they might be suitable for you.

Clinical Trial Focus Key Findings/Objectives Patient Population
Gestational Trophoblastic Neoplasia (GTN) Evaluating efficacy of dactinomycin alone vs. combination with toripalimab for FIGO scores 5-7 Patients with GTN
Rhabdomyosarcoma Assessing dactinomycin in combination therapies for newly diagnosed and relapsed cases Children and adults with rhabdomyosarcoma
Pharmacokinetics Study Characterizing plasma pharmacokinetics and metabolites of dactinomycin in pediatric patients Children with cancer
Advanced Melanoma Investigating dactinomycin with melphalan and ipilimumab in isolated limb infusion Patients with unresectable melanoma of the extremity
Germ Cell Tumors Evaluating dactinomycin in combination chemotherapy for relapsed germ cell tumors Patients with relapsed testicular cancer
Pleuropulmonary Blastoma Establishing treatment guidelines and analyzing outcomes for rare pediatric lung cancer Children with pleuropulmonary blastoma

FAQ

  • What is dactinomycin? Dactinomycin, also called Actinomycin D, is a chemotherapy drug used to treat various types of cancer. It works by interfering with the growth of cancer cells.
  • What types of cancer is dactinomycin being studied for? Clinical trials are exploring dactinomycin's use in gestational trophoblastic neoplasia, rhabdomyosarcoma, pleuropulmonary blastoma, germ cell tumors, and other rare cancers.
  • How is dactinomycin typically administered? Dactinomycin is usually given as an intravenous (IV) infusion. The dose and schedule can vary depending on the specific treatment protocol and type of cancer being treated.
  • What are some common combination therapies involving dactinomycin? Dactinomycin is often combined with other chemotherapy drugs like vincristine, ifosfamide, cyclophosphamide, and methotrexate in various treatment regimens.
  • What are some potential side effects of dactinomycin? Common side effects may include nausea, vomiting, hair loss, and increased risk of infection. Specific side effects can vary depending on the dosage and combination of drugs used.

Ongoing Clinical Trials on Dactinomycin

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +5

  • Study on Atypical Teratoid/Rhabdoid Tumors in Children Using Dactinomycin, Carboplatin, and Cyclophosphamide

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +6

Glossary

  • Gestational Trophoblastic Neoplasia (GTN): A group of rare tumors that form in the uterus from placental tissue after conception. It can occur after a normal pregnancy or miscarriage.
  • Rhabdomyosarcoma: A type of cancer that develops in soft tissue, particularly in skeletal muscles. It is most common in children and young adults.
  • Pleuropulmonary Blastoma (PPB): A rare childhood cancer that occurs in the lungs or in the pleura, the thin layer of tissue covering the lungs.
  • FIGO Score: A scoring system used to assess the severity and risk of gestational trophoblastic neoplasia, which helps guide treatment decisions.
  • β-human chorionic gonadotropin (β-hCG): A hormone produced during pregnancy that is used as a tumor marker in certain cancers, particularly gestational trophoblastic neoplasia.
  • Isolated Limb Infusion (ILI): A technique used to deliver high doses of chemotherapy directly to an arm or leg affected by cancer, while minimizing exposure to the rest of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Complete Remission: The disappearance of all signs of cancer in response to treatment.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.

References

  1. https://clinicaltrials.gov/study/NCT01464606
  2. https://clinicaltrials.gov/study/NCT00491946
  3. https://clinicaltrials.eu/trial/study-on-irinotecan-and-drug-combination-for-children-and-adults-with-frontline-and-relapsed-rhabdomyosarcoma/
  4. https://clinicaltrials.gov/study/NCT00541411
  5. https://clinicaltrials.gov/study/NCT06028672
  6. https://clinicaltrials.gov/study/NCT06309732
  7. https://clinicaltrials.gov/study/NCT01323517
  8. https://clinicaltrials.gov/study/NCT04388839